• video slide

    we work to decrease redundancy

    Breakthrough therapies research foundation

    we work to decrease redundancy increase the likelihood of a greater efficiency

Our Valued Services

What we Offer

Medical Research

A new paradigm for investigational drugs undergoing development has started. The Breakthrough therapy designation (BTD) has been introduced into the the US Food and Drug Administration (FDA)

Clinical Development

A new paradigm for investigational drugs undergoing development has started. The Breakthrough therapy designation (BTD) has been introduced into the the US Food and Drug Administration (FDA)

Biomarker Development

A new paradigm for investigational drugs undergoing development has started. The Breakthrough therapy designation (BTD) has been introduced into the the US Food and Drug Administration (FDA)

AITERO TEAM

Richard

Robert Imani

MD, PhD

Dr. Robert Imani is a prolific medical executive and entrepreneur. As the President and Founder of AITERO, Inc., the Advanced International Training Education Research Organization, he has over 22 years of practical medical experience on a global level. Creating a global medical platform, Dr. Imani's vision for AITERO is leading the company to make a difference and better the quality of life for people across the world. In addition to his role at the helm of AITERO, Dr. Imani is the Founder of BTRF, the Breakthrough Therapies Research Foundation, a non-profit working to advance medical discovery and research across a broad range of fields. Having already made strides in global product development teams, BTRF has brought forward proof-of-concept launches to the successful launch of oncology, metabolic resistance, CNS, and women's health therapeutics including Tarceva, Lupron, Kyprolis and Linzess.

Prior to founding his own organizations, Dr. Imani held several high-level positions in the healthcare field, including as Executive Medical Director at Onyx Pharmaceuticals, where he led immunotherapy programs for Blincyto, Kyprolis and Nexavar for the treatment of multiple myeloma, ALL, MCL and neuroendocrine tumors. He was the recipient of multiple awards in the Netherlands for his clinical research. Prompted into the medical profession by a drive to research and find solutions to problems, Dr. Imani studied at Erasmus University Rotterdam and EMCR before completing a Postdoctoral Fellowship in Cell/Cellular and Molecular Biology at the Stanford University School of Medicine. He has been published and contributed to articles extensively, on topics related to ovulation and infertility, and wrote his doctoral thesis on the prediction of ovulation induction outcome. Dr. Imani credits his success to being a highly strategic thinker and being a leader who is very oriented to results and performance. Known for his passion, entrepreneurial spirit, knowledge, drive and work ethic, he hopes to close the gaps of advanced computer systems, speed up the process of creating pharmaceuticals, and be able to distribute those pharmaceuticals in a shorter time frame. A resident of Encinitas, California, Dr. Imani is a member of the ASH, ASCO, EHA, DIA, ASRM and ESHRE.

Stay always updated

Latest News

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod

get in touch

Open for you

We're here

Postal Adress: 1902 Wright Place Suite xxx (TBD) Carlsbad, CA 92008

Phone: 760 918 5500

Email: info@aitero.com

With propositions

Contact Us